NASDAQ:CRVO CervoMed (CRVO) Stock Price, News & Analysis $9.49 +0.34 (+3.72%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CervoMed Stock (NASDAQ:CRVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CervoMed alerts:Sign Up Key Stats Today's Range$8.64▼$9.7050-Day Range$2.12▼$14.2952-Week Range$1.80▼$25.92Volume136,296 shsAverage Volume1.25 million shsMarket Capitalization$82.59 millionP/E RatioN/ADividend YieldN/APrice Target$27.50Consensus RatingModerate Buy Company OverviewCervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Read More… Remove Ads CervoMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreCRVO MarketRank™: CervoMed scored higher than 64% of companies evaluated by MarketBeat, and ranked 375th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCervoMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageCervoMed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CervoMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CervoMed are expected to grow in the coming year, from ($1.88) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CervoMed is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CervoMed is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCervoMed has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CervoMed's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted46.63% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CervoMed has recently increased by 190.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCervoMed does not currently pay a dividend.Dividend GrowthCervoMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted46.63% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CervoMed has recently increased by 190.70%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.27 News SentimentCervoMed has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for CervoMed this week, compared to 2 articles on an average week.Search Interest49 people have searched for CRVO on MarketBeat in the last 30 days. MarketBeat Follows30 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is an increase of 2,900% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CervoMed insiders have not sold or bought any company stock.Percentage Held by Insiders36.30% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.15% of the stock of CervoMed is held by institutions.Read more about CervoMed's insider trading history. Receive CRVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVO Stock News HeadlinesD. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO)March 28, 2025 | americanbankingnews.comChardan Capital Decreases Earnings Estimates for CervoMedMarch 28, 2025 | americanbankingnews.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.April 1, 2025 | Porter & Company (Ad)CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)March 25, 2025 | globenewswire.comResearch Analysts Issue Forecasts for CervoMed Q1 EarningsMarch 22, 2025 | americanbankingnews.comCervoMed Inc trading resumesMarch 21, 2025 | markets.businessinsider.comCervoMed Inc trading halted, volatility trading pauseMarch 21, 2025 | markets.businessinsider.com3CRVO : Peering Into CervoMed's Recent Short InterestMarch 19, 2025 | benzinga.comSee More Headlines CRVO Stock Analysis - Frequently Asked Questions How have CRVO shares performed this year? CervoMed's stock was trading at $2.34 at the beginning of 2025. Since then, CRVO stock has increased by 278.0% and is now trading at $8.8460. View the best growth stocks for 2025 here. How were CervoMed's earnings last quarter? CervoMed Inc. (NASDAQ:CRVO) posted its quarterly earnings results on Monday, March, 17th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.13. The business earned $2.16 million during the quarter, compared to analysts' expectations of $1.51 million. CervoMed had a negative net margin of 118.68% and a negative trailing twelve-month return on equity of 44.11%. How do I buy shares of CervoMed? Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CervoMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that CervoMed investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings3/17/2025Today3/31/2025Next Earnings (Estimated)4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVO Previous SymbolNASDAQ:CRVO CIK1053691 Webdiffusionpharma.com Phone14342200718Fax434-220-0722Employees4Year FoundedN/APrice Target and Rating Average Stock Price Target$27.50 High Stock Price Target$63.00 Low Stock Price Target$10.00 Potential Upside/Downside+200.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,170,000.00 Net Margins-118.68% Pretax Margin-118.68% Return on Equity-44.11% Return on Assets-39.81% Debt Debt-to-Equity RatioN/A Current Ratio15.04 Quick Ratio15.04 Sales & Book Value Annual Sales$7.14 million Price / Sales11.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book7.04Miscellaneous Outstanding Shares8,703,000Free Float3,930,000Market Cap$79.63 million OptionableNot Optionable Beta1.84 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CRVO) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.